Latest News and Press Releases

Helsinn Group and MEI Pharma Discontinue the Phase 3 Study with Pracinostat in AML after Completing Interim Analysis Lugano, Switzerland and San Diego, USA, July 2, 2020 – Helsinn, a Swiss...

Helsinn Group supports Conquer Cancer, the ASCO Foundation’s COVID Impacts Cancer fund Lugano, Switzerland, June 10, 2020 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer...

Helsinn announces launch of oral formulation of Akynzeo® in China Lugano, Switzerland, June 9, 2020 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and rare disease...

Helsinn announces FDA acceptance of IND application for TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities Lugano, Switzerland, June 8, 2020: Helsinn, a Swiss...

Helsinn Group announces FDA approval of a new liquid formulation of AKYNZEO® (fosnetupitant/palonosetron) injection in the United States Lugano, Switzerland, June 2, 2020 – Helsinn, a Swiss...

Helsinn Therapeutics (U.S.), Inc. waives copay fees for cancer-treating drug VALCHLOR® (mechlorethamine) gel to ensure eligible patients have access to treatment during the COVID-19 crisis Iselin,...

Helsinn announces European approval of the IV formulation of AKYNZEO® (fosnetupitant / palonosetron) Lugano, Switzerland, March 23, 2020 – Helsinn, the Swiss pharmaceutical group focused on building...

Helidon Xhixha and Giacomo “Jack” Bragliapresent the artwork The Twin Bottles: Message in a BottleAn environmental message Principality of Monaco, Yacht Club de Monaco Marina The Twin Bottles:...

New Insights on Mechlorethamine/Chlormethine gel presented at 4th World Congress of Cutaneous Lymphomas Lugano, Switzerland, February 14, 2020 – Helsinn, the Swiss pharmaceutical group focused on...

Lyfebulb and Helsinn Announce the Winners of the Third Annual Lyfebulb-Helsinn Cancer Innovation Summit & Award   MONACO, PRINCIPALITY OF MONACO, AND NEW YORK, NY, USA, January 31, 2020:...